Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CosiMaster
NCT07426484Phase 4Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2026
- Primary completion
- Dec 2030
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of cosibelimab-ipdl in cutaneous squamous cell carcinoma (cSCC), sponsored by Dana-Farber Cancer Institute. Started Apr 2026; status: recruiting.
02
Drugs
cosibelimab-ipdl
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT07426484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426484.